Biodefense Market Report 2026

The biodefense market size has grown strongly in recent years. It will grow from $20.23 billion in 2025 to $22.07 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing government biodefense funding, rising global health security concerns, expansion of national stockpiling programs, advancements in vaccine research platforms, strengthening of biosurveillance capabilities.

The biodefense market size is expected to see strong growth in the next few years. It will grow to $30.05 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing geopolitical instability risks, expansion of global disease monitoring networks, rising investments in next-generation vaccines, growing adoption of ai-driven threat analytics, increasing focus on rapid response biodefense systems. Major trends in the forecast period include increasing deployment of rapid biothreat detection systems, rising development of advanced medical countermeasures, growing investment in pandemic preparedness infrastructure, expansion of integrated emergency response platforms, enhanced focus on biothreat surveillance networks.

The ongoing risk of emerging infectious diseases is anticipated to drive expansion in the biodefense market. Infectious diseases are conditions triggered by harmful microorganisms like bacteria, viruses, parasites, or fungi that transmit directly or indirectly between individuals. The repeated emergence of these threats underscores escalating difficulties with pathogens, swift reactions, international collaboration, and readiness in biodefense efforts. Biodefense is vital for managing infectious diseases through improved preparation, early identification, and quick countermeasures against biological dangers, which helps reduce the effects of outbreaks on public health. For instance, in July 2024, the World Health Organization - a Switzerland-headquartered intergovernmental body - reported responding to 72 health crises in 2023, among them 19 grade-3 high-severity outbreaks, signaling a persistent rise in emerging infectious diseases from year to year. Thus, the continual danger of infectious diseases is fueling biodefense market growth.

Major companies in the biodefense sector are concentrating on innovative products, like nasal COVID-19 vaccines, to bolster worldwide readiness for biological risks. Nasal vaccines strengthen biodefense through simpler delivery, the possibility of mucosal immunity, less need for needles, better access, and potentially stronger immune reactions. For example, in January 2023, Bharat Biotech International Limited, an Indian biotech firm, introduced the iNCOVACC Nasal COVID-19 vaccine, which employs a recombinant replication-deficient adenovirus vector and includes a pre-fusion stabilized spike protein. Following successful phase I, II, and III clinical trials, this vaccine uses intranasal drops for administration. It involves nasal drops totaling 8 drops (0.5 mL per dose), with 4 drops per nostril, given as two doses spaced 4 weeks apart.

In September 2023, the Norway-based nonprofit Coalition for Epidemic Preparedness Innovations (CEPI), dedicated to accelerating vaccine development and epidemic preparedness, partnered with Indonesia's leading state-owned vaccine producer Bio Farma to enhance rapid manufacturing of outbreak vaccines. This collaboration aims to build mRNA and viral-vector "rapid-response" production capacity at Bio Farma, speeding up vaccine output and reserving slots for Global South countries during future epidemics; Bio Farma, which offers a wide range of WHO-prequalified vaccines, will utilize CEPI's support to construct GMP-standard facilities and bioprocess labs for advanced technologies.

Major companies operating in the biodefense market are Pfizer Inc., Johnson & Johnson, Merck & Co., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca Plc, GSK plc, Gilead Sciences Inc, Novavax Inc, Ichor Medical Systems, Emergent BioSolutions Inc., Alnylam Pharmaceuticals Inc., Dynavax Technologies, Bavarian Nordic, Siga Technologies Inc., Elusys Therapeutics Inc., Ology Bioservices, Altimmune Inc., Hytest Limited, XOMA Corporation, Cleveland BioLabs Inc., Inovio Pharmaceuticals Inc, Dynport Vaccine Company, ViralClear Pharmaceuticals.

North America was the largest region in the biodefense market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biodefense market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biodefense market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biodefense market by increasing costs of imported laboratory equipment, diagnostic reagents, sensors, protective gear, and advanced manufacturing inputs used in vaccine production and detection systems. North America and Europe are most affected due to reliance on specialized imported components, while Asia-Pacific faces cost pressure in large-scale manufacturing and export of biodefense technologies. These tariffs are increasing procurement costs for public health agencies and delaying deployment timelines. However, they are also encouraging domestic production of critical biodefense supplies, strengthening local manufacturing resilience, and supporting long-term national security objectives.

The biodefense market research report is one of a series of new reports that provides biodefense market statistics, including biodefense industry global market size, regional shares, competitors with a biodefense market share, detailed biodefense market segments, market trends and opportunities, and any further data you may need to thrive in the biodefense industry. This biodefense market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biodefense involves the strategies and measures put in place to safeguard against biological threats, such as the intentional dispersal of pathogens or biotoxins. It encompasses the creation of detection technologies, vaccines, therapies, and contingency plans for emergencies to lessen the effects of biological assaults on public health and security. Biodefense further includes research initiatives and policy measures aimed at preventing the abuse of biological agents.

The primary categories of biodefense include anthrax, smallpox, botulism, radiation or nuclear threats, and additional ones. Anthrax is a severe infectious illness caused by the bacterium Bacillus anthracis, which impacts both people and animals. It spreads via skin exposure, breathing in spores, or swallowing them. Devices for detecting biothreats - such as samplers, detectors or triggers, identifiers, assays, and more - find use in settings like hospitals and clinics, ambulatory care centers, and others.

The biodefense market consists of revenues earned by entities by providing services such as threat assessment, surveillance, training, consultation, strategy development, emergency planning, and facility management. The market value includes the value of related goods sold by the service provider or included within the service offering. The biodefense market also includes sales of detection equipment, personal protective gear, vaccines and pharmaceuticals, biological agent identification kits, biocontainment equipment, emergency response kits, biosecurity systems, and communication systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.